ELDN News

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

The End of Shots? 5 Biotech Stocks Rethinking Diabetes

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting